- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
Background
Protein in the urine is a common finding on a urinalysis in clinical practice. This protein comes from the kidney generally because of damage to the glomerulus and/or renal tubules.1 The differential diagnosis of proteinuria can be broad, with the etiology falling into one of three classifications: transient, persistent, and benign.2
Did You Know?
- Glomerulonephritis is one cause of persistent proteinuria. The most common glomerulonephritis is IgA nephropathy.3
- IgA nephropathy is more prevalent in patients of east Asian descent and is often diagnosed in the second or third decades of life.3
- Proteinuria is a prognostic factor in IgA nephropathy, with higher levels associated with faster eGFR decline and progression to kidney failure.4
Why Attend This Webinar?
To enhance your understanding of the presentation, differential diagnosis, and workup of proteinuria. There is also the opportunity to explore the pathophysiology and risk of progression of IgA nephropathy and application of knowledge with hypothetical patient case.
What You Will Learn
- Definition of proteinuria and how it is measured
- Differential diagnosis of proteinuria
- Pathophysiology, diagnosis, and risk of progression in IgA nephropathy
References:
- Lewis G, Maxwell AP. Practitioner. 2013;257(1758):19-22, 2-3.
- Haider MZ, Aslam A. Proteinuria. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 33232060.
- Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 2021 Feb;361(2):176-194. doi: 10.1016/j.amjms.2020.10.003. Epub 2020 Oct 8. PMID: 33309134; PMCID: PMC8577278.
- Pitcher D, et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.
Speaker
Maryam Gondal, MBBS/MD
Medical Director, PKD Center of Excellence at Yale New Haven Health; Assistant Professor of Medicine at Yale School of Medicine; Medical Director for incenter and Home Dialysis at DaVita in New Haven, CTMaryam Gondal, MBBS/MD, is an Assistant Professor of Medicine at Yale School of Medicine. She is a graduate of Aga Khan University in Karachi, Pakistan.did her Internal Medicine Residency at Indiana University and subsequently completed nephrology fellowship training at Yale University. She is the Medical Director for the PKD Center of Excellence at Yale. Also serves as the Medical Director for in-center and home dialysis at New Haven DaVita. Dr Gondal sees a wide variety of renal pathology; including but not limited to ADPKD, glomerular disease, inherited kidney disease, end stage kidney disease and Geriatric Nephrology.
Moderators
Alf Carroll, DMSc, PA-C
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Alf Carroll, DMSc, PA-C is a Senior Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. He earned his Doctor of Medical Science in Healthcare Leadership, Master of Science in Physician Assistant Studies, and Bachelor of Science in Biology from Northeastern University in Boston, Massachusetts. Prior to joining Otsuka, Alf held a position at AstraZeneca Pharmaceuticals working with key health systems in New England, covering the cardiovascular, renal, endocrine, and respiratory areas. Prior to joining industry, he held full time clinical Physician Assistant roles in the Emergency Department at Massachusetts General Hospital and South Shore Hospital, as well as other part time roles in internal medicine in the Boston area.
Dr. Maryam Gondal is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Alf Carroll, DMSc, PA-C is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
July 2025 US.CORP.X.25.00141Registration
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
